DOCSLIB.ORG

O Cial Show Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
O Cial Show Guide Ocial Show Guide 20th anniversary since 1986 BioJapan Organizers Regenerative Medicine Japan Organizers BioJapan Organizing Committee Forum for Innovative Regenerative Medicine Japan Bioindustry Association / Japan Health Sciences Japan Bioindustry Association Foundation / Japan Association for Techno-innovation in JTB Communication Design, Inc. Agriculture, Forestry and Fisheries / Japan Biological Informatics Consortium / Japan Association of Bioindustries Executives / Japan Pharmaceutical Manufacturers Association / NPO Kinki Bio-industry Development Organization / Research Institute of Innovative Technology for the Earth / Pacifico Yokohama, Japan Forum for Innovative Regenerative Medicine ( ) ( ) JTB Communication Design, Inc. Oct. 10 Wed. – 12 Fri. Special Support from Special Cooperation from Concurrent with Platinum Sponsors Platinum Sponsors Gold Sponsors Silver Sponsors Bronze Sponsors PHC Corporation, Biomedical Division Formerly Known as Panasonic Healthcare, Biomedical Party Sponsor Media Partners Global Partners 4 BioJapan / Regenerative Medicine Japan 2018 ■ Outline 開催概要 Name BioJapan / Regenerative Medicine Japan 2018 名 称 BioJapan / 再生医療JAPAN 2018 th th 2018年10月10日（水）～12日（金） 10:00～17:00 Date & Time October 10 (Wed.) – 12 (Fri.), 2018 10:00-17:00 (Partnering from 8:30) 会 期 （パートナリングは8:30～） Venue Pacifico Yokohama Exhibition Hall A, B, C, D and Annex Hall 会 場 パシフィコ横浜 展示ホールA・B・C・D およびアネックスホール Organizer BioJapan 主 催 [BioJapan] BioJapan Organizing Committee BioJapan 組織委員会 Japan Bioindustry Association 一般財団法人バイオインダストリー協会 Japan Health Sciences Foundation 公益財団法人ヒューマンサイエンス振興財団 Japan Association for Techno-innovation in Agriculture, Forestry and 公益社団法人農林水産・食品産業技術振興協会 Fisheries 一般社団法人バイオ産業情報化コンソーシアム Japan Biological Informatics Consortium 日本バイオ産業人会議 Japan Association of Bioindustries Executives 日本製薬工業協会 Japan Pharmaceutical Manufacturers Association NPO 法人近畿バイオインダストリー振興会議 NPO Kinki Bio-industry Development Organization 公益財団法人地球環境産業技術研究機構 Research Institute of Innovative Technology for the Earth 一般社団法人再生医療イノベーションフォーラム Forum for Innovative Regenerative Medicine JTB Communication Design, Inc. 株式会社JTBコミュニケーションデザイン Regenerative Medicine Japan [再生医療JAPAN] Forum for Innovative Regenerative Medicine 一般社団法人再生医療イノベーションフォーラム Japan Bioindustry Association 一般財団法人バイオインダストリー協会 JTB Communication Design, Inc. 株式会社JTBコミュニケーションデザイン Special City of Yokohama Support from 特別協賛 横浜市 Special Cooperation Kanagawa Prefecture, City of Kawasaki 特別後援 神奈川県、川崎市 from Concurrent Japan Healthcare Venture Summit 2018 ジャパン・ヘルスケアベンチャー・サミット 2018 同時開催 with ME-BYO Japan 2018 ME-BYO Japan 2018 Supported by Cabinet Office / Ministry of Education, Culture, Sports, Science and Technology 後 援 内閣府、 文部科学省、 厚生労働省、 農林水産省、 経済産業省、 国立研究開発法人 / Ministry of Health, Labour and Welfare / Ministry of Agriculture, Forestry and 科学技術振興機構、 国立研究開発法人産業技術総合研究所、 国立研究開発法人 Fisheries of Japan / Ministry of Economy, Trade and Industry / Japan Science and Technology Agency / National Institute of Advanced Industrial Science and 新エネルギー・産業技術総合開発機構、 独立行政法人中小企業基盤整備機構、 国 Technology / New Energy and Industrial Technology Development Organization 立研究開発法人日本医療研究開発機構、 独立行政法人日本貿易振興機構、 国立研 / Organization for Small & Medium Enterprises and Regional Innovation, JAPAN 究開発法人農業・食品産業技術総合研究機構、 国立研究開発法人理化学研究所 / Japan Agency for Medical Research and Development / Japan External Trade Organization / National Agriculture and Food Research Organization / RIKEN BioJapan Organizing Committee BioJapan 組織委員会 Chairman Sakayu Shimizu 会 長 清水 昌 Chairman of Japan Bioindustry Association 一般財団法人バイオインダストリー協会 会長 (Professor Emeritus, Kyoto University) （京都大学名誉教授） Deputy Chairman Toichi Takenaka 副会長 竹中 登一 Chairman of Japan Health Sciences Foundation 公益財団法人ヒューマンサイエンス振興財団 会長 (Former Chairman of Astellas Pharma Inc.) （前アステラス製薬株式会社会長） Deputy Chairman Koichiro Aramaki 副会長 荒蒔 康一郎 President of Japan Association for Techno-innovation in Agriculture, Forestry and 公益社団法人農林水産・食品産業技術振興協会 会長 Fisheries （元キリンホールディングス株式会社会長） (Former Chairman of Kirin Holdings Company Ltd.) 副会長 三輪 清志 Deputy Chairman Kiyoshi Miwa 一般社団法人バイオ産業情報化コンソーシアム 会長 Chairman of Japan Biological Informatics Consortium （味の素株式会社 客員フェロー） (Visiting Fellow of Ajinomoto Co., Inc.) 副会長 荒蒔 康一郎 Deputy Chairman Koichiro Aramaki 日本バイオ産業人会議 世話人代表 Chairman of Japan Association of Bioindustries Executives （元キリンホールディングス株式会社会長） (Former Chairman of Kirin Holdings Company Ltd.) 副会長 中山 讓治 Deputy Chairman George Nakayama 日本製薬工業協会 会長 President of Japan Pharmaceutical Manufacturers Association （第一三共株式会社 会長） (Chairman and CEO of Daiichi Sankyo Co., Ltd.) 副会長 田中 隆治 Deputy Chairman Takaharu Tanaka NPO法人近畿バイオインダストリー振興会議 理事長 Chairman of NPO Kinki Bio-industry Development Organization （星薬科大学 学長） (President, Hoshi University) 副会長 茅 陽一 Deputy Chairman Yoichi Kaya 公益財団法人地球環境産業技術研究機構 理事長 President of Research Institute of Innovative Technology for the Earth （東京大学名誉教授） (Professor Emeritus, The University of Tokyo) 副会長 戸田 雄三 Deputy Chairman Yuzo Toda 一般社団法人再生医療イノベーションフォーラム 代表理事・会長 Chairman of Forum for Innovative Regenerative Medicine （元富士フイルム株式会社取締役副社長CTO） (Former Director Senior Executive Vice President CTO FUJIFILM Corporation) 委員長 永山 治 President Osamu Nagayama 一般財団法人バイオインダストリー協会 理事長 President of Japan Bioindustry Association （中外製薬株式会社代表取締役会長） (Chairman of the Board of Directors, Chairman and CEO of Chugai Pharmaceutical) 6 BioJapan / Regenerative Medicine Japan 2018 ■ Venue 会場構成 2F 1F Main Stage Open Stage Stage C Stage B Annex Hall F201 - F206 Partnering Area Digital Healthcare Zone Zone Smart Cell Industry Zone Stage D Stage A ■ Schedule スケジュール 8:30 9:00 9:30 10:00 16:30 17:00 17:30 18:00 Partnering Meetings 10/10 パートナリング (Wed.) Exhibition Trade Exhibition 展示会 Presentation in Exhibition Hall Exhibitor Presentations / Open Stage Seminars / Main Stage Seminars / Presenters 10/12 展示会場内プレゼンテーション 出展者プレゼンテーション・オープンステージセミナー・メインステージセミナー・プレゼンターズ Seminars in Annex Hall 10/10 (Wed.) 10/10 (Wed.) Organizer Seminars / Sponsor Seminars / Luncheon Seminars (Fri.) Opening Ceremony Keynote Lectures アネックスホール内セミナー 開会式 基調講演 主催者セミナー・スポンサーセミナー・ランチョンセミナー Networking Parties ネ ット ワ ー キ ン グ パ ー ティ (Day 1) Welcome Reception (Day 2) Partnering Party Oct. 10 (Wed.) Oct. 11 (Thu.) Registration: 17:00 Open: 17:00 Start: 17:30* Start: 17:30 Yokohama Bay Hotel Tokyu The Grand Oriental Minato Mirai (Approx. 3 min. walk from Pacifico Yokohama) (Approx. 7 min. walk from Pacifico Yokohama) *A partnering participant badge is required for entry *A partnering participant badge is required for entry 【 会 期 初 日 】レセプション 【会期2日目】パートナリングパーティ 10月10日（水） 10月11日（木） 17：00～受付開始 17:00～ 受付開始 17：30～開宴 17：30～ 開宴 横浜ベイホテル東急 グランドオリエンタルみなとみらい （パシフィコ横浜から徒歩3分） （パシフィコ横浜から徒歩7分） ※関係業界の来賓、ならびにマッチングメンバー ※マッチングメンバー専用のバッジで に登録している来場者を交えたレセプション ご入場いただけます。 を開催いたします。マッチングメンバー専用 バッジでご入場いただけます。 Partnering Party Sponsor Partnering Party Supporters (In No Particular Order) BioJapan / Regenerative Medicine Japan 2018 7 Regenerative B BioJapan R P Partnering Medicine Japan ■ Exhibitors / Presenters / Partnering Participants S Seminar Country Booth ▶ University of California San Donnelley Financial Solutions ▶ GE Healthcare Finland Company / No. Diego P Region Japan ▶ LAKKA Technologies KOR Bio-Industry Division of METI S 1ST Biotherapeutics P Doshisha University C-70 B ▶ Modulight CHN BioIVT USA C-25 B 3D Medicines Inc. P DOT WORLD C-24 B ▶ MVision AI BIO-NET Leipzig DEU P A AbbVie P Dow Corning Toray R-10 R ▶ Navigil CHN Biotechgate CHE B-28 B TWN AbbVie P Drug Commercialization Center P ▶ OLKIControl USA Biotechnology and AbbVie P DyDo Group Holdings P ▶ Sitra Pharmaceutical Industries ABE, IKUBO & KATAYAMA P TWN C-54 B E e Therapeutics GBR P Promotion Office, MOEA, ▶ South Karelia Social and Health AbTLAS KOR P Economic Affairs Bureau City of Care District TAIWAN D-22 B Yokohama ▶ Turku Science Park aceRNA Technologies P Biovill Japan A-13 B Edmund Optics Japan R-29 R ▶ VideoVisit Global ACRO Biomedical TWN R-71 R Biowebspin CHE P Ehime University Forum for Innovative Adamed Pharma POL P BL&H USA USA P C-72 B R-74 R (Protein Island Matsuyama) Regenerative Medicine (FIRM) AGC Biologics USA C-03 B Boehringer Ingelheim Japan C-15 B Eisai P ▶ BrightPath Biotherapeutics AJINOMOTO C-43 B BRIM Biotechnology TWN P Eisai Korea KOR P ▶ MEDINET Albcura TWN B-43 B Bristol-Myers Squibb P ▶ Metcela Alfresa Pharma P Brooks Japan R-39 R EKO INSTRUMENT B-24 B ▶ Nippi Alira Health FRA P Buddha International Medical NEP P Foundation for Biomedical Allegro IP Law Firm P Centre Research and Innovation at S Eli Lilly and Company USA P Almac Discovery GBR P Building Block Science in Kobe Graduate School of Frontier D-43 B Eli Lilly Japan P AMBICION R-22 R Foundation for Promotion Biosciences, Osaka University AMRA Medical SWE P Embassy of Canada to Japan CAN D-58 B of Material Science and R-59 R Bukwang Pharm KOR P Andy Pharma Partners P ▶ BIOTECanada Technology of Japan C Caladrius Biosciences USA P AOP Orphan Pharmaceuticals GBR P ▶ Aspect Biosystems FOXO KOR R-62 R Canine-Lab B-18 B ▶ WEX Pharmaceuticals Fraunhofer Institute for Cell Ardelyx USA P DEU P CEFO KOR P Therapy and Immunology ARII - Agence Régionale Embassy of Canada in Seoul KOR P pour l’Innovation et Ehime University (Protein Island Embassy of the Kingdom of the Frost & Sullivan Japan S FRA P C-72 B NLD D-51 B l’Internationalisation des Matsuyama) Netherlands Fuji Yakuhin P ▶ entreprises CellFree Sciences ▶ Invest in Holland FUJIFILM R-09 R Asahi Kasei P Cell Innovation Partners P ▶ LipoCoat ▶ FUJIFILM Cellular Dynamics ESP KOR ASCIL Biopharm P Cellivery Therapeutics P ▶ LURIS ▶ FUJIFILM Wako Pure Chemical ASICON Tokyo / microfluidic
Load more

Recommended publications
  • SAN JUAN BASIN PUBLIC HEALTH Chief Strategy Officer
    SAN JUAN BASIN PUBLIC HEALTH CLASS SPECIFICATION Chief Strategy Officer JOB FAMILY BAND/GRADE/SUBGRADE FLSA STATUS Management E81 Exempt CLASS SUMMARY: This class is the second level in a three-level Management Series. Incumbents serve as a high- level leader and strategist devoted to the management and administration of divisions and functions, reporting to the Executive Director, but working in close collaboration with the Deputy Director of Operations and the Deputy Director of Administrative Services. Incumbents apply advanced management principles to formulate, facilitate and communicate the organization’s vision, initiatives and goals. Incumbents; represent SJBPH; act as an advisor to the chief executive officer and to the Board of Health; develop and implement programs critical to SJBPH; and exercise control and supervision of multiple assigned functions and/or divisions and significant resources/assets. Within the incumbant’s designated division, managerial oversight and responsibilities cross multiple functional units within the organization. The position is responsible for program outcomes across a designated department, as assigned. Incumbents supervise management staff including overseeing and conducting performance evaluations, coordinating training; and implementing hiring, discipline and termination procedures. ESSENTIAL DUTIES: This class specification represents only the core areas of responsibilities; specific position assignments will vary depending on the needs of SJBPH. Supervises staff including overseeing and conducting
    [Show full text]
  • Mckinsey Special Collection the Role of the CFO
    McKinsey Special Collection The Role of the CFO Selected articles from the Strategy and Corporate Finance Practice The Role of the CFO articles Why CFOs need a bigger role in business transformations Ryan Davies and Douglas Huey April 2017 read the article Are today’s CFOs ready for tomorrow’s demands on finance? Survey December 2016 read the article Profiling the modern CFO A panel discussion October 2015 read the article Building a better partnership between finance and strategy Ankur Agrawal, Emma Bibbs and Jean-Hugues Monier October 2015 read the article The Role of the CFO McKinsey Special Collection 3 © Martin Barraud/Getty Images Why CFOs need a bigger role in business transformations CFO involvement can lead to better outcomes for organization-wide performance improvements. Ryan Davies and Douglas Huey When managers decide that a step change in that underlie a transformation. And they often have performance is desirable and achievable, they’ll an organization-wide credibility for measuring often undertake a business transformation. value creation. The way it usually works, though, is Such transformations are large-scale efforts that that CEOs sponsor transformations. A full-time run the full span of a company, challenging executive—often a chief transformation officer— the fundamentals of every organizational layer. assumes operational control, and individual That includes the most basic processes in business units take the lead on their own perfor- everything from R&D, purchasing, and production mance. That often leaves CFOs on the sidelines, to sales, marketing, and HR. And the effect on providing transaction support and auditing the earnings can be substantial—as much as 25 percent transformation’s results.
    [Show full text]
  • Inside the C-Suite: the CEO, the Board, and the ELT
    Center for Executive Succession Inside the C-Suite: The CEO, the Board, and the ELT Results of the 2017 HR@Moore Survey of Chief HR Officers Patrick M. Wright Anthony J. Nyberg Donald J. Schepker Ormonde R. Cragun Christina B. Hymer From the: Center for Executive Succession Department of Management Darla Moore School of Business University of South Carolina Executive Summary The 2017 HR@Moore Survey of Chief HR Officers asked respondents to provide information on the relationships among those in the C-suite and the board. The results revealed that half of the respondents reported that their CEO also served as the Chairman of the Board (indicating there is a separate Lead Director), while the other half had an Non-Executive Independent Chairman of the Board (Non-executive Chair). Non-executive Chairs tended to exert greater monitoring of the CEO and provide more advice relative to Lead Directors. There did not seem to be any differences in the effectiveness of the relationship or the level of collaboration between the CEO and the Non-executive Chair or the Lead Director. However, higher levels of trust existed between This and cover photo courtesy of the University of South Carolina the CEO and the Lead Director than between the Athletics Communications and Public Relations Department CEO and the Non-executive Chair. When asked In terms of dynamics among the ELT, CEOs were about the kinds of tensions that existed between most likely to rely on the CHRO as a confidant, the CEO and either the Non-executive Chair or followed by the CFO and the President/COO.
    [Show full text]
  • Radiology Department Report 2017–2019
    Radiology Department Report 2017–2019 Radiology Department Report 2017–2019 Contents Letter from the Chair 2 Clinical Divisions 84 In Memoriam 6 Research Divisions 92 Canary Center at Stanford for Cancer Radiology Faculty 8 Early Detection 94 Department Leadership 10 Integrative Biomedical Imaging All Faculty 14 Informatics at Stanford (IBIIS) 100 New Faculty Appointments 18 Molecular Imaging Program at Stanford (MIPS) 106 Faculty Leadership Appointments 26 Precision Health and Integrated New Chair of Biomedical Data Science 27 Diagnostics (PHIND) Center at Stanford 120 radiology.stanford.edu Faculty Retirements and Recalls 28 Radiological Sciences Laboratory (RSL) 128 Faculty Departures 29 Faculty Honors and Awards 30 Feature: IMMERS 33 Active Sponsored Research 138 Future Faculty and Staff 34 Funded Projects Summary 149 Feature: 3DQ Lab 37 Equipment 38 Radiology Snapshot 150 Feature: Industry Collaborations 40 Radiology Family 152 Translational Research 42 Artificial Intelligence in Radiology 44 Thank You to our Colleagues 154 Theragnostics: Combining Diagnostic and Therapeutic Radiopharmaceuticals to Fight Cancer 50 Acknowledging our Diagnostic Ultrasound through a Different Lens 52 Generous Supporters 156 Cover Image Training Programs 54 Shear waves were induced in a cylindrical gelatin phantom using a mechanical vibra- Clinical Training Programs 56 How you can tor, causing them to scatter and reflect. Their displacements were imaged using a phase- Graduating Residents 60 Support the Department 157 contrast 3T MRI technique (MR elastography). This work highlights the importance of image reconstruction algorithms. Each individual wave image (represented by each Graduating Fellows 64 circle) is chaotic and difficult to interpret by itself. However, thousands of wave images can Research Training Programs 69 Canary Challenge 158 be thoughtfully fused together using an image reconstruction algorithm to produce a single Graduating PhDs 73 image representing the gelatin’s mechanical properties.
    [Show full text]
  • Corporate Governance Statement 2020
    Corporate governance statement This corporate governance statement is prepared in Corporate accordance with Chapter 7, Section 7 of the Finnish Securities Markets Act (2012/746, as amended) and the Finnish governance Corporate Governance Code 2020 (the “Finnish Corporate Governance Code”). statement Introduction In 2020, we continued delivering on Nokia’s commitment to strong corporate governance and related practices. To do that, the Board activities are structured to develop the company’s strategy and to enable the Board to support the management on the delivery of it within a transparent governance framework. The table below sets out a high-level overview of the key areas of focus for the Board’s and its Committees’ activities during the year in addition to regular business and financial updates at each Board meeting and several reviews of the impacts and actions relating to the COVID-19 pandemic. January February/March April May July September/October December Board – Digitalization update – CEO change – Transformation update – Technology Strategy update – Annual sustainability review – Annual strategy meeting – Annual plan and long-range plan – Ethics & compliance and litigation – Postponing 2020 AGM due to – Convening the remote AGM – Digitalization update – Key market strategies – New operating model planning – Enterprise Risk Management update COVID-19 – Appointment of the new – Business group strategy planning – Board evaluation – Remuneration Policy to be Board Chair presented to the AGM – Nokia Equity Program 2020 Corporate
    [Show full text]
  • Chief Strategy Officer Summit Gain Greater Insight with Strategic Planning
    Chief Strategy Officer Summit Gain greater insight with strategic planning March 25 & 26, 2014 Intercontinental Grand Stanford Hong Kong Speakers Include: Confirmed Speakers: • Simeon Preston, Group Chief Strategy & Operations Officer, AIA • Matthew Smith, Global Head of Transformational Strategy, Cisco Systems • Tiziana Figliolia, Director, Strategic Planning Program, Emerging Markets, Autodesk • Kam Soon Siew, Head of Strategic Planning, Harley-Davidson • Leo Burnett, Chief Strategy Officer, Leo Burnett • Michael, Huddart, EVP & CEO, Manulife • Ayhan Siriner, Head of Strategy & Marketing, APAC, Osram • Jerry Lou, Chief Strategy Officer, Morgan Stanley • Carina Ho, Senior VP, Global Strategy & Development, Schneider Electric • Andy Liu, VP, Strategy & Business Development, Asia Pacific, IMS Health • Craig Dungey, Head of Strategy, Asia Pacific, Aon Benfield • Patrick Lau, Managing Director, Head of M&A, China Construction Bank Intl • Martin Thaysen, Vice President, CEVA Logistics • Robin Speculand, Chief Executive Officer, Bridges Business Consultancy Who Will You Meet? There is no question that IE. provides the gold standard events in the industry and will Job Title Of Attendees connect you with decision makers within the Attendees are at Director analytics industry. You will be meeting 82% senior level executives from major level or above corporations and innovative small to medium size companies. President 3% /Principal 21% Company Size Of Attendees SVP/VP 1000+ Employees 300-999 Employees 50-299 Employees 12% C-Level Less than 49 Employees 42% Snr. Director /Director 56% 81% 25% Attendees are companies with at least 300 employees Global Head 13% / Head 11% Snr. Manager 8% 8% /Manager Academic (1%) Past Delegates Include • Head of Strategic Planning, DBS Bank • Associate Dir.
    [Show full text]
  • MFHA's 2013 Tribute to Hispanic/Latino Leadership In
    MFHA’s 2013 Tribute to Hispanic/Latino Leadership in Foodservice & Hospitality Valerie Insignares Jose Luis Prado Enrique Ramirez Dan Kiernan Jose Dias Pablo Graf President President Chief Financial Officer Executive Vice President Executive Vice President Senior Vice President LongHorn Steakhouse Quaker Foods Pizza Hut Operations Global Development and Southwest Asia Operations Darden North America Yum! Brands, Inc. Olive Garden President of Latin America Hyatt Hotels Corporation PepsiCo Darden & Carribean Burger King Corporation Bernard Acoca Bea Perez Senior Vice President Chief Sustainability Category Brand Valentin Ramirez J.C. Gonzalez-Mendez Officer Multicultural Foodservice & Vice President and General Senior Vice President The Coca-Cola Company Management, Americas Hospitality Alliance Starbucks Coffee Company Manager of Diversified Global Corporate Social Brands & Business Responsibility, Sustainability Development & Philanthropy McCormick & Company, Inc. McDonald’s Corporation Michael Montelongo Charlie Vizoso Oscar Budejen Senior Vice President Vice President Vice President Public Policy & Lourdes F. Diaz Strategy & Program Norma Barnes-Euresti Channel Growth Corporate Affairs Vice President Diversity Management Office Vice President and ARAMARK Higher Sodexo North America Relations ARAMARK Healthcare Chief Counsel Education Sodexo Labor-Employment & Intellectual Property Martha Tomas Flynn Javier Benito Kellogg Company Director Chief Strategy Officer Global Development Services Yum! Brands, Inc. Dunkin’ Brands, Inc. PREMIER ` DIAMOND GOLD SILVER BRONZE PARTNER SUPPORTER AdvancePierre Foods The MATLET Group Corner Bakery Café BJ’s Restaurants, Inc. The Bama Companies Marriott International, Inc. Culver’s The Cheesecake Factory, Inc. Ben E. Keith Foods MGM Resorts International Kimpton Hotels & Restaurants Legal Sea Foods Choice Hotels International OTG Management Oakwood Temporary Housing Perkins & Marie Callendar’s, Inc. Gordon Food Service Romano’s Macaroni Grill Starbucks Coffee Company Red Roof Innc, Inc.
    [Show full text]
  • Chief Strategy Officer Summit Direction, Vision, Strategy
    Chief Strategy Officer Summit Direction, Vision, Strategy December 2 & 3, 2014 Crowne Plaza Times Square New York Confirmed Speakers Confirmed Speakers: • Senior Vice President Corporate Strategy and Development, National Geographic • Section Chief, Strategy & Integration, US Federal Government • Senior Vice President & Chief Strategy Officer, Washington Redskins • Chief Revenue Officer, Tough Mudder • Chief Strategy Officer, USAA • Revenue Chief of Staff, Tough Mudder • Founder, CEO, The Mom Complex • Strategy Execution, & Transformation, Target • Chief Strategy Officer, Mashable • Vice President, Corporate Strategy, PepsiCo • Chief Strategy and Financial Officer, WWE • Chief Knowledge Officer, NASA • Chief Knowledge Officer, US Army • Chief Business Officer, Chartbeat • Chief Information Officer, U.S. Department of Energy Why Attend? The Chief Strategy Officer Summit is the platform to meet and greet with leaders within strategy. • Chief Strategy Officer • Corporate Strategic Planning • Planning & Control • Strategic Planning & Analysis • Strategy & Development • Business Analysis • Market Research • Business Planning • Forecasters At this summit we will question the role of the chief strategy officer and how it has developed over the last couple of years. More importantly we will join together chief strategy officers and get their opinion of where their role is going. The CSO confronts company wide issues, a role which was solely appointed to the CEO. This summit delves into where the creation of the role came from, why it came about and what the benefits are. We also look into the role and its importance because a chief strategy officer has significant responsibility for a handful of major business functions and activities. The two days of presentations and interactive sessions will allow for investigation, learning and development meaning you will return to the office equipped with some fantastic key takeaways.
    [Show full text]
  • Porter Novelli
    Porter Novelli Applying the Drotter “Results Based” Leadership Pipeline Approach to create a Performance Management System in a Professional Service Firm INTRODUCTION.................................................................................................................................................... 311 BUSINESS DIAGNOSIS AND ASSESSMENT ................................................................................................................ 311 FEEDBACK............................................................................................................................................................... 314 PROGRAM DESIGN CONSIDERATIONS ..................................................................................................................... 315 PROGRAM IMPLEMENTATION........................................................................................................................ 317 PERFORMANCE MANAGEMENT SYSTEM DEVELOPMENT ................................................................... 321 EVALUATION......................................................................................................................................................... 325 ABOUT THE AUTHOR.......................................................................................................................................... 326 Introduction The Drotter results-based approach is tailored to a professional services firm structure and applied in the development of a performance management system aligned with
    [Show full text]
  • How Starbucks Responded Amidst a Racial Sensitivity Crisis
    Pepperdine Journal of Communication Research Volume 7 Article 4 2019 $16.7 Million To Save One Reputation: How Starbucks Responded Amidst a Racial Sensitivity Crisis Monica Avila Pepperdine University, [email protected] Hannah Parkin Pepperdine University, [email protected] Sabrina Galoostian Pepperdine University, [email protected] Follow this and additional works at: https://digitalcommons.pepperdine.edu/pjcr Part of the Communication Commons Recommended Citation Avila, Monica; Parkin, Hannah; and Galoostian, Sabrina (2019) "$16.7 Million To Save One Reputation: How Starbucks Responded Amidst a Racial Sensitivity Crisis," Pepperdine Journal of Communication Research: Vol. 7 , Article 4. Available at: https://digitalcommons.pepperdine.edu/pjcr/vol7/iss1/4 This Article is brought to you for free and open access by the Communication at Pepperdine Digital Commons. It has been accepted for inclusion in Pepperdine Journal of Communication Research by an authorized editor of Pepperdine Digital Commons. For more information, please contact [email protected], [email protected], [email protected]. Pepperdine Communication Research Journal 24 $16.7 Million To Save One Reputation: How Starbucks Responded Amidst a Racial Sensitivity Crisis Monica Avila, Hannah Parkin & Sabrina Galoostian Written for COM 492: Public Relations Case Studies and Insights (Dr. Klive Oh) Organization Profile worldwide (Starbucks). The company first Overview of Case opened its doors in 1971 to the city of Seattle, In April of 2016, two black men were Washington with the goal of serving the world’s sitting in a Starbucks store (Gayle, 2018) when an best cup of coffee. Howard Schultz, past employee claimed they had to leave since they had chairman and chief executive officer of Starbucks, not made a purchase.
    [Show full text]
  • Centerwatch Weekly, August 19, 2019
    Join the CenterWatch Community! CenterWatch August 19, 2019 Weekly Industry Briefs…2 Up and Coming…3 Drug & Device Pipeline News…7 Industry Seeks More Detail from FDA Guidance Nine drugs and devices have entered a new on Trial Diversity trial phase this week. By Colin Stoecker Roche/Genentech wrote, such as those JobWatch…8 he FDA’s draft guidance on broaden- with other conditions, unique racial ing eligibility criteria and increasing characteristics and varying age and diversity in clinical trials needs more body profile. T CLINICAL TRIAL RISK definition and depth, according to drugmak- In addition to sponsors, CROs and aca- AND PERFORMANCE ers, clinical trial organizations and patients demic research centers, more than half of MANAGEMENT SUMMIT responding to the agency’s call for com- the comments were from individuals, many ments on the document. representing the EndBrainCancer Initiative, A common theme in the 90 separate a patient advocacy organization. The draft comments on the guidance was the lack of guidance, Enhancing the Diversity of Clini- SEPT. 4–5, 2019 REGISTER TODAY clarity on how to determine a representative cal Trial Populations, was issued in June PHILADELPHIA participant sample. Several commenters (CenterWatch, June 10, 2019). asked the FDA to develop a statistical model The FDA needs to “more clearly eluci- NEW WHITE PAPERS AVAILABLE or metric to help sponsors design trials date the scientific reasons for its focus on An Actionable Approach An Actionable Approach to Decentralized Clinical Trials to and set eligibility criteria that result in an diversity,” the Brigham and Women’s Hos- Grow Enrollment and Retention to Decentralized adequate patient sample.
    [Show full text]
  • Announcement of Executive Officers' Change
    FOR IMMEDIATE RELEASE Announcement of Executive Officers’ Change Tokyo, Japan, February 21, 2020 – Hitachi High-Tech Corporation (TSE: 8036) today announced the change of Executive Officers. 1. Promotion [Effective April 1, 2020] New Title Name Current Position (As of February 21, 2020) Representative Senior Vice President and Executive Officer, General Executive Officer, Manager, Corporate Manufacturing Strategy Div., Executive Vice Joji Honda and President, Hitachi High-Tech Fine Systems President and Corporation Executive Officer Senior Vice President Takashi Iizumi Vice President and Executive Officer, CDO and Executive Officer Vice President and Executive Officer, and General Senior Vice President Futoshi Ishiwa Manager, Nano-Technology Solution Business and Executive Officer Group Vice President and Executive Officer, CHRO, CRO, and General Akira Ietsugu Executive Officer Manager, Human Resources & General Affairs Div. Vice President and Hitoshi Kato Executive Officer, CSO Executive Officer Vice President and Kazuo Executive Officer, CMO, and General Manager, Executive Officer Karasawa Global Business Strategy Div. 2. New Appointment [Effective April 1, 2020] New Title Name Current Position (As of February 21, 2020) Deputy General Manager, Nano-Technology Osamu Executive Officer Solution Business Group, and General Manager, Komuro Metrology and Analysis Systems Product Div. Deputy General Manager, Analytical & Medical Yoshimitsu Executive Officer Solution Business Group, and General Manager, Takagi Medical Systems Sales & Marketing
    [Show full text]